CORE--PATHOLOGY

核心--病理学

基本信息

批准号：
7490032
负责人：
ANDREW P EVAN
金额：
$ 12.92万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-01 至 2010-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7490032
关键词：
Apatites Bariatrics Biopsy Biopsy Specimen Calculi Crystal Formation Cystinuria Deposition Detection Electrons Fluorescence Microscopy Genetic Growth Human Hyperparathyroidism Ileostomy Image Immunohistochemistry Intestinal Bypasses Kidney Kidney Calculi Label Light Lithium Localized Location Measurement Microscopic Minerals Obesity Osteoblasts Papillary Pathology Patients Pattern Proteins Rate Rattus Research Personnel Reverse Transcriptase Polymerase Chain Reaction Sampling Serum Site Spectroscopy, Fourier Transform Infrared Staining method Stains Standards of Weights and Measures Techniques Tetracycline Tetracyclines Tissues Transcript Transmission Electron Microscopy Uric Acid Urine alpha-Fetoproteins bikunin brushite human tissue hypercalciuria inhibitor/antagonist kidney cortex light microscopy light transmission osteopontin particle prothrombin fragment 1 tongue papilla urinary

项目摘要

The Pathology Core has been highly successful in the identification of tissue changes and characterizing sites of mineral deposition as well as crystal type in three different type of human stone patients (common CaOx, intestinal bypass patients for obesity with renal stones and brushite) and the GHS rats. In the renewal, this core will oversee and conduct all morphological analyses for Projects by Lingeman and Evans using 1) light micrscopy with special stains to characterize the histopathological patterns and mineral composition of crystal deposition in our new groups of human stone formers (apatite including RTAs, primary hyperparathyroidism, ileostomy, cystinuria, uric acid stones, bariatric and CaOx with high urine pH (> pH 6.3), 2) light and transmission electron microscopic immunohistochemistry to detect the presence of a select group of known inhibitor proteins of crystal formation (osteopontin, prothombin fragment 1, fetuin-A and bikunin) in the interstitium and at the stone-plaque interface, 3) mu CT imaging to quantitate, localize and characterize mineral type of new sites of crystal deposition in whole kidneys or biopsies samples. 4) mu FTIR and electron diffraction detection techniques to identify specific sites of crystal deposition in human biopsy samples and GHS rat kidneys, 5) RT-PCR techniques to determine the presence of osteoblast-like transcripts in the interstitium of the common CaOx stone formers vs intestinal bypass or bariatric stone formers, 6) determine the mechanisms of crystal particle formation and coalescence in CaOx stone formers by quantitating particle growth/coalescence and performing double labeling, tetracyline studies to determine the rate of crystal formation, 7) provide cortical biopsy samples to Project by Coe for VDR analysis and verification of biopsy location, and 8) to assess the GHS rat for plaque formation. Project by Lingeman will supply biopsy samples from the kidney (cortex to papilla) of predetermined groups of human stone formers. Dr. Willis will perform serum and urinary lithium analyses for Project by Coe.

病理核心在识别组织变化和表征矿物沉积的部位以及三种不同类型的人类石材患者（常见的Caox，肠道旁门患者肥胖的肾结石和刷子）和GHS大鼠的晶体类型。在续签中，该核心将通过Lingeman和Evans对项目进行监督和进行所有形态分析，使用1）具有特殊污渍的光微观，以表征我们在新的人类石材形成群中（包括RTAS，主要的高甲状腺功能障碍，高甲状腺肿，磷灰石）中晶体沉积的组织病理学模式和矿物质组成。 ileostomy, cystinuria, uric acid stones, bariatric and CaOx with high urine pH (> pH 6.3), 2) light and transmission electron microscopic immunohistochemistry to detect the presence of a select group of known inhibitor proteins of crystal formation (osteopontin, prothombin fragment 1, fetuin-A and bikunin) in the interstitium and at the stone-plaque界面，3）MU CT成像以定量，定位和表征整个肾脏或活检样品中晶体沉积的矿物质类型。 4）MU FTIR和电子衍射检测技术，以确定人体活检样品和GHS大鼠肾脏中晶体沉积的特定位点，5）RT-PCR技术，以确定在普通的Caox Stone Myners vs Intersinal Bypass或Bariatric Stonemertic Stonemertic Stonemertic Stonemertic石材中的存在中成骨细胞样的转录物的存在通过定量颗粒的生长/合并并进行双重标记，四环素研究以确定晶体形成的速率，7）通过定量颗粒的生长/合并和进行双重标记，在Caox石材形成中形成晶体颗粒形成和聚结的机制，7）7）通过COE提供了COE的皮质活检样品，以进行VDR分析和验证活检位置的验证，以及8）以评估GHS的斑块形成。 Lingeman的Project将提供预定的人类石材组群的肾脏（皮质到乳头皮层）的活检样本。威利斯博士将对COE进行Project的血清和尿锂分析。